The Diabetes Control and Complications Trial

The gift that keeps giving

Eric S. Kilpatrick, Alan S. Rigby, Stephen Atkin

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

The Diabetes Control and Complications Trial (DCCT) recruited its first patients in 1983. In 1993, the investigators reported that intensive glycemic treatment of patients with type 1 diabetes mellitus was superior to conventional therapy in preventing the development of microvascular and neurological complications and thus provided definitive proof of the relationship between hyperglycemia and the subsequent risk of diabetic retinopathy, nephropathy and neuropathy. The value of this study, however, did not end there. After the original trial, most participants of the DCCT continued to be followed up in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, which demonstrated the long-term benefits of close glycemic control and provided observational data of a large epidemiological cohort of patients with type 1 diabetes mellitus. Stored samples from the DCCT have also provided an invaluable resource for the identification of new markers of the disease. Recently, the complete dataset of the DCCT and of the initial years of the EDIC have been made publicly available, which allowed independent investigators to help answer their own questions about diabetes. In conclusion, the DCCT continues to provide new insights into type 1 diabetes mellitus, which are of benefit to patients over a quarter of a century after the trial was started.

Original languageEnglish
Pages (from-to)537-545
Number of pages9
JournalNature Reviews Endocrinology
Volume5
Issue number10
DOIs
Publication statusPublished - Oct 2009
Externally publishedYes

Fingerprint

Gift Giving
Diabetes Complications
Type 1 Diabetes Mellitus
Epidemiology
Research Personnel
Diabetic Neuropathies
Diabetic Nephropathies
Diabetic Retinopathy
Hyperglycemia
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The Diabetes Control and Complications Trial : The gift that keeps giving. / Kilpatrick, Eric S.; Rigby, Alan S.; Atkin, Stephen.

In: Nature Reviews Endocrinology, Vol. 5, No. 10, 10.2009, p. 537-545.

Research output: Contribution to journalReview article

Kilpatrick, Eric S. ; Rigby, Alan S. ; Atkin, Stephen. / The Diabetes Control and Complications Trial : The gift that keeps giving. In: Nature Reviews Endocrinology. 2009 ; Vol. 5, No. 10. pp. 537-545.
@article{d954c771bb7942d6b3361d6810bf5777,
title = "The Diabetes Control and Complications Trial: The gift that keeps giving",
abstract = "The Diabetes Control and Complications Trial (DCCT) recruited its first patients in 1983. In 1993, the investigators reported that intensive glycemic treatment of patients with type 1 diabetes mellitus was superior to conventional therapy in preventing the development of microvascular and neurological complications and thus provided definitive proof of the relationship between hyperglycemia and the subsequent risk of diabetic retinopathy, nephropathy and neuropathy. The value of this study, however, did not end there. After the original trial, most participants of the DCCT continued to be followed up in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, which demonstrated the long-term benefits of close glycemic control and provided observational data of a large epidemiological cohort of patients with type 1 diabetes mellitus. Stored samples from the DCCT have also provided an invaluable resource for the identification of new markers of the disease. Recently, the complete dataset of the DCCT and of the initial years of the EDIC have been made publicly available, which allowed independent investigators to help answer their own questions about diabetes. In conclusion, the DCCT continues to provide new insights into type 1 diabetes mellitus, which are of benefit to patients over a quarter of a century after the trial was started.",
author = "Kilpatrick, {Eric S.} and Rigby, {Alan S.} and Stephen Atkin",
year = "2009",
month = "10",
doi = "10.1038/nrendo.2009.179",
language = "English",
volume = "5",
pages = "537--545",
journal = "Nature Reviews Endocrinology",
issn = "1759-5029",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - The Diabetes Control and Complications Trial

T2 - The gift that keeps giving

AU - Kilpatrick, Eric S.

AU - Rigby, Alan S.

AU - Atkin, Stephen

PY - 2009/10

Y1 - 2009/10

N2 - The Diabetes Control and Complications Trial (DCCT) recruited its first patients in 1983. In 1993, the investigators reported that intensive glycemic treatment of patients with type 1 diabetes mellitus was superior to conventional therapy in preventing the development of microvascular and neurological complications and thus provided definitive proof of the relationship between hyperglycemia and the subsequent risk of diabetic retinopathy, nephropathy and neuropathy. The value of this study, however, did not end there. After the original trial, most participants of the DCCT continued to be followed up in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, which demonstrated the long-term benefits of close glycemic control and provided observational data of a large epidemiological cohort of patients with type 1 diabetes mellitus. Stored samples from the DCCT have also provided an invaluable resource for the identification of new markers of the disease. Recently, the complete dataset of the DCCT and of the initial years of the EDIC have been made publicly available, which allowed independent investigators to help answer their own questions about diabetes. In conclusion, the DCCT continues to provide new insights into type 1 diabetes mellitus, which are of benefit to patients over a quarter of a century after the trial was started.

AB - The Diabetes Control and Complications Trial (DCCT) recruited its first patients in 1983. In 1993, the investigators reported that intensive glycemic treatment of patients with type 1 diabetes mellitus was superior to conventional therapy in preventing the development of microvascular and neurological complications and thus provided definitive proof of the relationship between hyperglycemia and the subsequent risk of diabetic retinopathy, nephropathy and neuropathy. The value of this study, however, did not end there. After the original trial, most participants of the DCCT continued to be followed up in the Epidemiology of Diabetes Interventions and Complications (EDIC) study, which demonstrated the long-term benefits of close glycemic control and provided observational data of a large epidemiological cohort of patients with type 1 diabetes mellitus. Stored samples from the DCCT have also provided an invaluable resource for the identification of new markers of the disease. Recently, the complete dataset of the DCCT and of the initial years of the EDIC have been made publicly available, which allowed independent investigators to help answer their own questions about diabetes. In conclusion, the DCCT continues to provide new insights into type 1 diabetes mellitus, which are of benefit to patients over a quarter of a century after the trial was started.

UR - http://www.scopus.com/inward/record.url?scp=70349442506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349442506&partnerID=8YFLogxK

U2 - 10.1038/nrendo.2009.179

DO - 10.1038/nrendo.2009.179

M3 - Review article

VL - 5

SP - 537

EP - 545

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

SN - 1759-5029

IS - 10

ER -